(19)

(11)

EP 4 247 401 A1

(12)

(43) Date of publication: 27.09.2023 Bulletin 2023/39 (21) Application number: 21895640.7 (22) Date of filing: 19.11.2021

(51) International Patent Classification (IPC):  A61K 38/00(2006.01) C07K 7/04(2006.01) C07K 19/00(2006.01) A61K 38/08(2019.01) C07K 7/06(2006.01) C12N 15/62(2006.01) (52) Cooperative Patent Classification (CPC): A61K 38/00; A61P 35/00; C07K 14/82; C12Y 306/05; C12N 9/14; A61K 39/001164 (86) International application number: PCT/US2021/060013 (87) International publication number: WO 2022/109220 (27.05.2022 Gazette 2022/21)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA ME Designated Validation States: KH MA MD TN (30) Priority: 20.11.2020 US 202017100630 07.12.2020 US 202017114237 02.06.2021 US 202117336960 30.07.2021 US 202117389875 28.09.2021 US 202163249235 P (71) Applicant: Think Therapeutics, Inc. Newton, MA 02458 (US)

(72) Inventors: GIFFORD, David Newton, MA 02458 (US) CARTER, Brandon Cambrige, MA 02142 (US) (74) Representative: HGF  HGF Limited 1 City Walk Leeds LS11 9DX Leeds LS11 9DX (GB)